GW Pharmaceuticals PLC (NASDAQ:GWPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Monday.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

Other equities analysts have also recently issued reports about the stock. ValuEngine raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Maxim Group reissued a “buy” rating and set a $135.00 price target on shares of GW Pharmaceuticals PLC in a research report on Thursday, May 25th. BidaskClub raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. TheStreet cut shares of GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a research report on Wednesday, May 10th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $208.00 price target on shares of GW Pharmaceuticals PLC in a research report on Tuesday, May 9th. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $156.38.

GW Pharmaceuticals PLC (NASDAQ:GWPH) traded up 0.25% on Monday, hitting $115.21. The company had a trading volume of 222,523 shares. GW Pharmaceuticals PLC has a 12-month low of $79.62 and a 12-month high of $137.88. The firm’s 50 day moving average price is $102.65 and its 200 day moving average price is $114.18. The stock’s market cap is $2.92 billion.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.50) by $0.20. The business had revenue of $2.04 million for the quarter, compared to analyst estimates of $2.07 million. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. GW Pharmaceuticals PLC’s revenue was down 23.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.06) EPS. Equities analysts predict that GW Pharmaceuticals PLC will post ($5.10) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “GW Pharmaceuticals PLC (GWPH) Lowered to Hold at Zacks Investment Research” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/07/24/gw-pharmaceuticals-plc-gwph-lowered-to-hold-at-zacks-investment-research.html.

Large investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. raised its stake in shares of GW Pharmaceuticals PLC by 23.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,376 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 264 shares during the last quarter. Blair William & Co. IL acquired a new stake in shares of GW Pharmaceuticals PLC during the first quarter valued at about $207,000. Nwam LLC acquired a new stake in shares of GW Pharmaceuticals PLC during the first quarter valued at about $208,000. Ameriprise Financial Inc. acquired a new stake in shares of GW Pharmaceuticals PLC during the first quarter valued at about $230,000. Finally, Quantbot Technologies LP acquired a new stake in shares of GW Pharmaceuticals PLC during the first quarter valued at about $231,000. Hedge funds and other institutional investors own 75.63% of the company’s stock.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.